SimBioSys has entered a strategic collaboration with augmented reality (AR) firm Magic Leap to integrate AI and AR for improved cancer surgery outcomes.

This partnership aims to integrate TumorSight Viz, SimBioSys' AI-powered medical imaging tool, with Magic Leap's AR technology to optimise surgical precision, reduce invasiveness, and improve patient quality of life.

Approved by the US Food and Drug Administration (FDA), the TumorSight Viz offers 3D visualisations of breast cancer, aiding surgeons in effective planning and patient consultation.

The collaboration will explore incorporating this technology into Magic Leap 2, an enterprise-ready AR device, to provide surgeons with immersive insights into tumour localisation and the surrounding anatomy.

Magic Leap 2 features Dynamic Dimming technology and superior image quality.

According to the companies, this collaboration is expected to revolutionise the way surgeons interact with patient-specific data.

SimBioSys chief medical officer Barry Rosen said: "Like AI, the AR field has made incredible strides in recent years, with Magic Leap being a recognised market leader and trailblazer in the space.

“Unfortunately, other VR/AR approaches have failed in modalities such as breast cancer where the imaging does not reflect the patient’s position at surgery. SimBioSys has solutions coming to market soon that can adjust for this with our computation modelling capabilities and can help power AR in breast cancer to have real clinical utility.”

SimBioSys said the integrated SimBioSys and Magic Leap 2 workflow is currently not FDA-cleared for diagnostic use.

Last week, SimBioSys launched TumorSight Plan, a clinical decision support tool intended to help improve surgical planning for early-stage breast cancer.

TumorSight Plan is designed to offer advanced visualisation, best practices and data-driven insights for surgeons to support provider-patient interactions.